Some of these studies are particularly important because they suggest that apoA-I- and HDL-based therapies may improve glycaemic control in patients with T2D that have complete loss of β-cell function and are refractory to many of the currently available antidiabetic therapies [28,71]. Here, APOA1 is linked to type 2 diabetes mellitus.